國家衛生研究院 NHRI:Item 3990099045/2234
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 12145/12927 (94%)
造訪人次 : 858744      線上人數 : 753
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋
    主頁 ‧ 登入 ‧ 上傳 ‧ 說明 ‧ 關於NHRI ‧ 管理 到手機版


    請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/2234


    題名: Erlotinib response EGFR-mutant gefitinib-resistant non-small-cell lung cancer
    作者: Chang, JWC;Chou, CL;Huang, SF;Wang, HM;Hsieh, JJ;Hsu, T;Cheung, YC
    貢獻者: Division of Molecular and Genomic Medicine
    摘要: Purpose: Failure to gefitinib is generally believed to be associated with cross-resistance to other epidermal. growth factor receptor tyrosine kinase inhibitors (EGFR-TKI). Here we report a case whose active EGFR-mutant NSCLC responded to erlotinib treatment. Patient and methods: Lung specimen was obtained during diagnostic procedures from a 41-year-old Taiwanese mate smoker with adenocarcinoma. He received cisplatin-based chemotherapy following craniotomy to remove his brain metastasis. Tumor progressed in both lung and left adrenal gland. He underwent second-tine docetaxel chemotherapy. Tumor progressed again 7 months later. He was subsequently treated with gefitinib 250mg QD. Complete regression of the lung tumor and partial response of the left adrenal gland mass was achieved. Nine months later, the left lower lobe lung tumor and left adrenal gland tumor progressed. A tung biopsy from the left tower lobe disclosed an adenocarcinoma which harbored an in-frame deletion in exon 19 (heterozygous delE746-A750) of EGFR without a second mutation such as T790M in exon 20. Subsequent erlotinib 150 mg QD was administered. He experienced grade 1 skin rash, diarrhea and paronychia following erlotinib. Results: This patient achieved a partial response to erlotinib treatment. He remained on erlotinib for a total of 18 months until the left adrenal gland tumor progressed. Conclusions: This case demonstrated that NSCLC bearing in-frame deletion in exon 19 of EGFR may respond to erlotinib treatment following gefitinib failure. (c) 2007 Elsevier Ireland Ltd. All rights reserved.
    關鍵詞: Oncology;Respiratory System
    日期: 2007-12
    關聯: Lung Cancer. 2007 Dec;58(3):414-417.
    Link to: http://dx.doi.org/10.1016/j.lungcan.2007.05.018
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0169-5002&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000251596600017
    Cited Times(Scopus): http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=35748985588
    顯示於類別:[黃秀芬] 期刊論文

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    000251596600017.pdf413KbAdobe PDF750檢視/開啟


    在NHRI中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋